You are surely correct and yet things are so corrupt I think it could surely go that way. I was getting emails from the head of ALZ ORG telling everyone to work for it's approval. Sent him one asking how much they were paying him and how he slept at night
Recent BIIB News
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/29/2026 09:00:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 10:40:54 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 10:05:42 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 08:42:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 08:34:27 PM
- Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region • GlobeNewswire Inc. • 04/20/2026 11:30:00 AM
- Form SC TO-T - Tender offer statement by Third Party • Edgar (US Regulatory) • 04/14/2026 11:02:46 AM
- Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 04/06/2026 10:08:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/06/2026 10:31:37 AM
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 04/03/2026 09:10:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:05:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 09:03:19 PM
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 03/31/2026 09:01:35 PM
- Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology • GlobeNewswire Inc. • 03/31/2026 10:59:00 AM
- Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology • GlobeNewswire Inc. • 03/31/2026 10:59:00 AM
- FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity • GlobeNewswire Inc. • 03/28/2026 07:00:00 PM
- Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026 • PR Newswire (US) • 03/20/2026 04:05:00 PM
- Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Biogen shares Phase 1b findings for salanersen in spinal muscular atrophy • IH Market News • 03/11/2026 03:09:29 PM
- Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy • GlobeNewswire Inc. • 03/11/2026 12:00:00 PM
- Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences • GlobeNewswire Inc. • 03/05/2026 12:30:00 PM
- The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome • GlobeNewswire Inc. • 03/04/2026 10:05:00 PM
